Effectiveness of Influenza Vaccination and Early Antiviral Treatment in Reducing Pneumonia Risk in Severe Influenza Cases.

antiviral treatment influenza pneumonia vaccination

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
07 Feb 2024
Historique:
received: 27 12 2023
revised: 24 01 2024
accepted: 01 02 2024
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: epublish

Résumé

Influenza vaccination may be effective in preventing influenza infection and may reduce the risk of influenza-associated pneumonia. The study aim was to evaluate the effect of influenza vaccination in preventing pneumonia when it failed to prevent influenza hospitalization. This was a case-control study comparing hospitalized cases of influenza with and without pneumonia in patients aged ≥18 years in 16 hospitals in Catalonia over 10 influenza seasons (2010-11 to 2019-20). Data on sociodemographic, virological characteristics, comorbidities, vaccination history, and antiviral treatment were collected and analysed. The crude odds ratio (OR) and adjusted OR (aOR) with the corresponding 95% confidence interval (CI) values were calculated. In total, 5080 patients hospitalized for severe influenza were included, 63.5% (3224/5080) of whom had pneumonia-mostly men (56.8%; 1830/3224) and mostly in the ≥75 age group (39.3%; 1267/3224)-and of whom 14.0% died (451/3224). Virus A and virus B accounted for 78.1% (2518/3224) and 21.9% (705/3224) of influenza types, respectively. Starting antiviral treatment ≤48 h after symptom onset (aOR = 0.69; 95%CI: 0.53-0.90) and a history of seasonal influenza vaccination (aOR = 0.85; 95%CI: 0.72-0.98) were protective factors in developing pneumonia. Adherence to seasonal influenza vaccination and starting antiviral treatment within 48 h of symptom onset can reduce pneumonia risk in severe influenza cases.

Identifiants

pubmed: 38400156
pii: vaccines12020173
doi: 10.3390/vaccines12020173
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Pere Godoy (P)

Institut de Recerca Biomédica de Lleida (IRBLleida), Universitat de Lleida, 25006 Lleida, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.

Núria Soldevila (N)

CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.
Departament de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain.

Ana Martínez (A)

CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.
Agència de Salut Pública de Catalunya, 08005 Barcelona, Spain.

Sofia Godoy (S)

Institut de Recerca Biomédica de Lleida (IRBLleida), Universitat de Lleida, 25006 Lleida, Spain.
Institut Català de la Salut, 08007 Lleida, Spain.

Mireia Jané (M)

CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.
Agència de Salut Pública de Catalunya, 08005 Barcelona, Spain.

Nuria Torner (N)

CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.
Agència de Salut Pública de Catalunya, 08005 Barcelona, Spain.

Lesly Acosta (L)

Agència de Salut Pública de Catalunya, 08005 Barcelona, Spain.

Cristina Rius (C)

CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.
Agència de Salut Pública de Barcelona, 08023 Barcelona, Spain.

Àngela Domínguez (À)

CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.
Departament de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain.

Classifications MeSH